RainPath AI
RainPath AI digitizes and accelerates pathology by converting unstained biopsy images into colorized views that match conventional histological stains, enabling faster tissue review without chemical dyes. The company applies advanced AI models for virtual staining and image analysis to recreate stains such as hematoxylin and eosin and to support slide-level diagnostics. RainPath AI operates as a B2B digital pathology solution focused on laboratory and clinical pathology workflows and automation. Its technology reduces dependence on manual staining and technician time while speeding report generation for pathology teams.
RainPath AI
RainPath AI digitizes and accelerates pathology by converting unstained biopsy images into colorized views that match conventional histological stains, enabling faster tissue review without chemical dyes. The company applies advanced AI models for virtual staining and image analysis to recreate stains such as hematoxylin and eosin and to support slide-level diagnostics. RainPath AI operates as a B2B digital pathology solution focused on laboratory and clinical pathology workflows and automation. Its technology reduces dependence on manual staining and technician time while speeding report generation for pathology teams.
TL;DR
What they do: AI-powered virtual staining that converts unstained biopsy images into diagnostic-quality, colorized views
Products: RainFlow (workflow, scanning, report drafting) and RainHub (quotation/charge optimization, file management)
HQ / region: La Mézière, Bretagne, France
Funding: Seed round ~€2.7M (Jul 2025) with multiple European investors
Company Overview
Problem Domain
Digital pathology, virtual staining, pathology workflow automation
Founded
2025
Industry
DeepTech
Funding Track Record
€2.7M
Investors reported to include Bpifrance, Xplore, Teampact Ventures, Sharpstone Capital, Advans Lab and The Quest
Investor Signal
“Participated by European institutional and venture investors including Bpifrance and several early-stage funds”